$3.24
2.99% yesterday
Nasdaq, Jun 11, 10:18 pm CET
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

ImmunityBio Inc Stock price

$3.24
+0.88 37.29% 1M
+0.09 2.86% 6M
+0.68 26.56% YTD
-2.72 45.64% 1Y
-3.44 51.46% 5Y
-31.40 90.65% 10Y
-31.40 90.65% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.10 2.99%
ISIN
US45256X1037
Symbol
IBRX
Sector
Industry

Key metrics

Market capitalization $2.86b
Enterprise Value $3.58b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 114.67
P/S ratio (TTM) P/S ratio 91.60
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 10,306.67%
Revenue (TTM) Revenue $31.22m
EBIT (operating result TTM) EBIT $-313.42m
Free Cash Flow (TTM) Free Cash Flow $-376.91m
Cash position $61.59m
EPS (TTM) EPS $-0.47
P/E forward negative
P/S forward 29.62
EV/Sales forward 37.08
Short interest 32.28%
Show more

Is ImmunityBio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,837 stocks worldwide.

ImmunityBio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a ImmunityBio Inc forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a ImmunityBio Inc forecast:

Buy
100%

Financial data from ImmunityBio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
31 31
10,307% 10,307%
100%
- Direct Costs 0.06 0.06
-
0%
24 24
-
77%
- Selling and Administrative Expenses 160 160
15% 15%
511%
- Research and Development Expense 183 183
10% 10%
586%
-311 -311
9% 9%
-998%
- Depreciation and Amortization 2 2
0% 0%
6%
EBIT (Operating Income) EBIT -313 -313
9% 9%
-1,004%
Net Profit -409 -409
32% 32%
-1,310%

In millions USD.

Don't miss a Thing! We will send you all news about ImmunityBio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ImmunityBio Inc Stock News

Neutral
Business Wire
9 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a well-established root cause of early mortality in patients with cancer across all tumor types, correlates with significant improved survival. While an...
Neutral
Business Wire
10 days ago
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Expanded Access authorization for the use of its Cancer BioShield™ platform, anchored by ANKTIVA® (nogapendekin alfa inbakicept-pmln), to treat lymphopenia in adult patients with refractory or relapsed solid tumors ...
Neutral
Business Wire
16 days ago
CULVER CITY, Calif. & RIYADH, Saudi Arabia--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the signing of a strategic Memorandum of Understanding (MOU) with the Ministry of Investment of Saudi Arabia (MISA), King Faisal Specialist Hospital & Research Centre (KFSHRC), and King Abdullah International Medical Research Center (KAIMRC). This multi...
More ImmunityBio Inc News

Company Profile

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in Culver City, CA.

Head office United States
CEO Richard Adcock
Employees 680
Founded 2014
Website immunitybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today